Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

NCT07810088 | Recruiting Phase 2

• 1 other identifier: OBU-BC-II-205
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a prospective, single-arm, multicenter phase II clinical trial. The study plans to enroll 40 patients with HR+/HER2- advanced breast cancer to explore the efficacy and safety of patients receiving olmesartan, dalpiciclib and aromatase inhibitor treatment.

Conditions

HR+ / HER2- Advanced Breast Cancer

Keywords

dalpiciclib; olmesartan; HR+/HER2- advanced breast cancer

Outcome Measures

Primary Outcomes (1)

• Progession-free survival

  PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.

  Up to 2 years

Secondary Outcomes (3)

• overall Survival

  up tp 3 years

• Objective response rate(ORR)

  up to 1 years

• Disease control rate(DCR)

  up to 1 years

Other Outcomes (1)

• The Treatment-Emergent adverse event rate according to the Common Terminology Criteria for Adverse Events version 5.0

  up to 2 years

Study Arms (1)

treatment

EXPERIMENTAL

dalpiciclib+olmesartan+ letrozole or anastrozole or exemestane or Fulvestrant

Drug: Treatment

Interventions

Treatment DRUG

dalpiciclib:125mg once a day for 3 weeks and stop for 1 week. Q4W.

treatment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Women aged 18 to 75 years, either pre-menopausal/post-menopausal or post-menopausal.
• Histologically confirmed HR+/HER2- locally advanced or metastatic breast cancer. Specific definition: Immunohistochemical detection of ER \> 10% positive tumor cells is defined as ER positive, PR \> 10% positive tumor cells is defined as PR positive, and ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 ++ but negative after FISH detection without amplification is defined as HER2 negative;
• Have not received any systemic treatment for local recurrence or metastatic diseases before.
• Recurrence occurred more than 12 months after the completion of adjuvant endocrine therapy.
• According to the RECIST 1.1 , at least one measurable lesion.
• Eastern Cooperative Oncology Group (ECOG) physical condition score is 0-1.
• The functional of organs are normal:
• Pregnant women of childbearing age must have undergone a serum pregnancy test 28 days before enrollment, and the result is negative. patients are willing to use a medically approved highly effective contraceptive method during the study period and within 1 year after the last administration of the study drug.
• Non-pregnant or non-lactating female patients.
• Not participating in other ongoing studies .
• With the consent of the patient or their legal representative and having signed the informed consent form, willing and capable of following the planned visits, study treatment plan, laboratory tests and other trial procedures.

You may not qualify if:

• Any evidence of severe or uncontrollable systemic diseases, including active bleeding disorders, active infections (such as hepatitis B, hepatitis C and human immunodeficiency virus), or severe damage to bone marrow reserves or organ functions (such as liver and kidney damage).
• Previous use of CDK4/6 inhibitors.
• Active brain metastases or meningeal brain metastases.
• Upper limb arterial blood pressure lower than 90/60 mmHg.
• Any history of malignant tumors other than breast cancer within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin or squamous cell carcinoma.
• Severe pneumonia history such as interstitial pneumonia.
• At the time of starting the study treatment, the patient has not recovered from any CTCAE ≥ 3 grade toxicity caused by previous treatment.
• Had any heart disease, including: (1) requiring drug treatment or clinically significant arrhythmia; (2) myocardial infarction; (3) heart failure; (4) any other heart disease judged by the researcher or sponsor as not suitable for participating in this trial; etc.
• Significant comorbidities, including mental disorders that the investigator or sponsor considers would adversely affect the patient's participation in the study.
• History of immunodeficiency diseases, including positive HIV testing, or having other acquired or congenital immune deficiency diseases, or having a history of organ transplantation and allogeneic bone marrow transplantation; history of interstitial lung disease, non-infectious pneumonia.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

Study Sites (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Interventions

Therapeutics

Study Officials

• yanxia zhao, master

  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

yanxia zhao

CONTACT

+8613407192551; Sophia7781@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: August 24, 2026
• First Posted: September 9, 2026
• Study Start: June 28, 2025
• Primary Completion (Estimated): June 28, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: September 9, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)